Related Experiment Video
Updated: Jun 23, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Canadian Cardiovascular Society Clinical Practice Update on Contemporary Management of the Patient With Hypertrophic
Andrew M Crean1, Arnon Adler2, Laura Arbour3
1Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada; North West Heart Center, Manchester, United Kingdom.
Insights
This clinical practice update offers practical guidance on hypertrophic cardiomyopathy (HCM) care for general cardiologists. It distills expert experience for effective diagnosis, treatment, and risk assessment in HCM patients, including pediatric considerations.
Area of Science:
- Cardiology
- Clinical Practice Guidelines
- Cardiovascular Medicine
Background:
- Numerous hypertrophic cardiomyopathy (HCM) guidelines exist but are often lengthy and less accessible to non-specialists.
- This document synthesizes practical experience and peer-reviewed literature for effective HCM management.
- It targets general cardiologists and cardiovascular practitioners, not solely HCM specialists.
Purpose of the Study:
- To provide a concise, experience-based concentrate on essential hypertrophic cardiomyopathy (HCM) care.
- To distill the essence of effective and appropriate HCM management for a broader clinical audience.
- To offer practical insights beyond traditional, lengthy guidelines.
Main Methods:
- Expert consensus opinion derived from extensive practical experience and literature review.
- Focus on key aspects of HCM: diagnosis, obstruction identification, imaging, genetic testing, and therapeutics.
- Inclusion of pediatric considerations and sudden cardiac death risk assessment.
Main Results:
- Comprehensive overview of hypertrophic cardiomyopathy (HCM) clinical presentation and diagnosis.
- Emphasis on identifying and managing obstruction in HCM.
- Review of cardiac magnetic resonance imaging, genetic testing, and treatment options, including cardiac myosin inhibitors.
Conclusions:
- This update provides practical, experience-driven insights for managing hypertrophic cardiomyopathy (HCM).
- It covers essential elements from diagnosis to end-stage care, including pediatric nuances.
- Emphasizes expert judgment over dogma in individual patient management.
Abstract:
Numerous guidelines on the diagnosis and management of hypertrophic cardiomyopathy (HCM) have been published, by learned societies, over the past decade. Although helpful they are often long and less adapted to nonexperts. This writing panel was challenged to produce a document that grew as much from years of practical experience as it did from the peer-reviewed literature. As such, rather than produce yet another set of guidelines, we aim herein to deliver a concentrate of our own experiential learning and distill for the reader the essence of effective and appropriate HCM care. This Clinical Practice Update on HCM is therefore aimed at general cardiologists and other cardiovascular practitioners rather than for HCM specialists. We set the stage with a description of the condition and its clinical presentation, discuss the central importance of "obstruction" and how to look for it, review the role of cardiac magnetic resonance imaging, reflect on the appropriate use of genetic testing, review the treatment options for symptomatic HCM-crucially including cardiac myosin inhibitors, and deal concisely with practical issues surrounding risk assessment for sudden cardiac death, and management of the end-stage HCM patient. Uniquely, we have captured the pediatric experience on our panel to discuss appropriate differences in the management of younger patients with HCM. We ask the reader to remember that this document represents expert consensus opinion rather than dogma and to use their best judgement when dealing with the HCM patient in front of them.
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Pathophysiology of Heart Failure
Pathophysiology of Cardiac Performance
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

